Retraction Watch reports that PNAS has issued expressions of concern about two papers from Ohio State's Carlo Croce.
Ohio State University's Carlo Croce is facing new allegations of research misconduct, according to the New York Times.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.
Ohio State's Steve Rissing writes that gene drives may be helpful, but also may be harmful.
With the funding, OSU researchers will conduct cardiovascular phenotyping and exome sequencing of DCM patients of European, African, and Hispanic ancestry.
The database currently includes 60 oncogenes with variants associated with therapies and clinical trials, or that have been functionally characterized.
The trial combines clinical NGS panels with research-based exome and transcriptome sequencing.
The paper describes a method of identifying genetic markers for reconstructing the phylogeny of the Penstemon genus from low coverage WGS data.
Affymetrix has been awarded
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.